NCT06567743: Brief Title: Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC |
|
|
| Recruiting | 2 | 50 | US | Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM | CG Oncology, Inc. | High-Risk Non-Muscle-Invasive Bladder Cancer | 03/27 | 12/27 | | |